These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2901345)

  • 21. Activation of Ha-ras p21 by substitution, deletion, and insertion mutations.
    Chipperfield RG; Jones SS; Lo KM; Weinberg RA
    Mol Cell Biol; 1985 Aug; 5(8):1809-13. PubMed ID: 3018526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.
    Qiu FH; Ray P; Brown K; Barker PE; Jhanwar S; Ruddle FH; Besmer P
    EMBO J; 1988 Apr; 7(4):1003-11. PubMed ID: 2456920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R.
    Shu HK; Pelley RJ; Kung HJ
    J Virol; 1991 Nov; 65(11):6173-80. PubMed ID: 1681117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.
    Siegel PM; Muller WJ
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):8878-83. PubMed ID: 8799121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF; Heffernan PA; Weinberg RA
    Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.
    Margolis BL; Lax I; Kris R; Dombalagian M; Honegger AM; Howk R; Givol D; Ullrich A; Schlessinger J
    J Biol Chem; 1989 Jun; 264(18):10667-71. PubMed ID: 2543678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
    Peles E; Levy RB; Or E; Ullrich A; Yarden Y
    EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
    van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R
    Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
    Brandt-Rauf PW; Rackovsky S; Pincus MR
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
    Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
    Bargmann CI; Weinberg RA
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.
    Messerle K; Schlegel J; Hynes NE; Groner B
    Mol Cell Endocrinol; 1994 Oct; 105(1):1-10. PubMed ID: 7821711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein.
    Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
    Acta Oncol; 1992; 31(2):147-50. PubMed ID: 1352454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
    Reardon DB; Hung MC
    J Biol Chem; 1993 Aug; 268(24):18136-42. PubMed ID: 7688739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
    Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational activation of c-raf-1 and definition of the minimal transforming sequence.
    Heidecker G; Huleihel M; Cleveland JL; Kolch W; Beck TW; Lloyd P; Pawson T; Rapp UR
    Mol Cell Biol; 1990 Jun; 10(6):2503-12. PubMed ID: 2188091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional heterogeneity of proto-oncogene tyrosine kinases: the C terminus of the human epidermal growth factor receptor facilitates cell proliferation.
    Velu TJ; Vass WC; Lowy DR; Beguinot L
    Mol Cell Biol; 1989 Apr; 9(4):1772-8. PubMed ID: 2786142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.
    Flanagan JG; Leder P
    Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8057-61. PubMed ID: 2903500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of non-ras transforming genes in chemical carcinogenesis.
    Cooper CS
    Environ Health Perspect; 1991 Jun; 93():33-40. PubMed ID: 1685444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.